How will we use the new antiviral agents for hepatitis B?
- Robert P. Perrillo MD
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
There are two licensed drugs for chronic hepatitis B virus (HBV), interferon alfa and lamivudine, with similar efficacy rates. Lamivudine is less expensive and better tolerated than interferon alfa and is the drug of choice for patients with decompensated cirrhosis and recurrent HBV infection after liver transplantation. The major problem with lamivudine monotherapy has been the emergence of drugresistant HBV polymerase (YMDD) mutants. Thus, longterm use of lamivudine in other settings remains somewhat controversial. Alternative nucleoside analogues that are active against both wild-type and YMDD-mutant HBV are currently being tested. It is hoped that a combination of one or more of these agents with lamivudine will not only prove more effective than lamivudine alone but also decrease the rate of lamivudine resistance. Preliminary studies suggest that the combination of interferon and lamivudine is associated with an enhanced rate of virologic response when compared with either agent alone. From a theoretical perspective, the combination of interferon with one or more nucleoside analogues may be the most effective way to treat HBV infection in many clinical situations.
- Greenberg HB, Pollard RB, Lutwick LI, et al.: Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976, 295:517–522. CrossRef
- Hoofnagle JH, Peters M, Mullen KD, et al.: Randomized, controlled trial of recombinant human alpha interferon in patients with chronic hepatitis B. Gastroenterology 1988, 95:1318–1325.
- Perrillo RP, Schiff ER, Davis GL, et al.: A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal, for the treatment of chronic hepatitis B. N Engl J Med 1990, 323:295–301. CrossRef
- Hoofnagle JH, Hanson RG, Minuk GY, et al.: Randomized, controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology 1984, 86:150–157.
- Perrillo RP, Regenstein FG, Bodicky CJ, et al.: Comparative efficacy of adenine arabinoside 5′ monophosphate and prednisone withdrawal followed by adenine arabinoside 5′ monophosphate in the treatment of chronic active hepatitis type B. Gastroenterology 1985, 88:780–786.
- Gish RG, Lau JYN, Brooks L, et al.: Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996, 23:1–7. CrossRef
- McKenzie R, Fried MW, Sallie R, et al.: Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside for hepatitis B. N Engl J Med 1995, 336:1099–1105. CrossRef
- Tyrrell DLJ, Mitchell MC, De Man RA, et al.: Phase II trial of lamivudine for chronic hepatitis B [abstract]. Hepatology 1993, 18:112A. CrossRef
- Dienstag JL, Schiff ER, Wright TL, et al.: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999, 341:1256–1263. This report describes the results of a multicenter placebo-controlled trial. Thirty-two percent of 66 treated patients lost HBeAg antigen, and histologic response was documented. HBsAg clearance was not observed. YMDD mutants were documented in 32% of those tested, and posttreatment ALT flares occurred in 25% of treated patients, compared with 8% of the placebo group. CrossRef
- Lai C-L, Chien R-N, Leung NWY, et al.: A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998, 339:61–68. This is a placebo-controlled trial in 358 Asian patients with normal ALT and mild hepatitis at baseline in one third of patients. Loss of HBeAg was observed in 16% of patients treated with lamivudine monotherapy for 52 weeks, compared with 4% of those given placebo. Lamivudine-resistant mutants occurred in 14% of patients, in each case after 9 months of therapy. CrossRef
- Atkins M, Hunt CM, Brown N, et al.: Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients [abstract]. Hepatology 1998, 28:319A.
- Leung NWY, Lai C-L, Chang T-T, et al.: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001, 33:1527–1532. After 3 years of treatment with lamivudine, 40% of 58 patients achieved HBeAg seroconversion, and response frequency was 65% in patients whose baseline ALT level exceeded two times the upper limit of normal. Unfortunately, lamivudine resistance was confirmed in 57% of patients at the 3-year mark. CrossRef
- Chang TT, Liaw YF, Guan R, et al.: Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years [abstract]. Antivir Ther 2000, 5(suppl1):44.
- Lok AS, Heathcote EJ, Hoofnagle JH: Management of hepatitis B: 2000-Summary of a workshop. Gastroenterology 2001, 120:1828–1853. This is a concise review of the epidemiology, virology, natural history, immunopathogenesis, and treatment options for patients with chronic HBV infection. The authors have assembled leading authorities in the field, and they propose treatment recommendations as well as future directions for research.
- Wong DKH, Cheung AM, O‘Rourke K, et al.: Effect of alpha interferon treatment in patients with hepatitis B e antigenpositive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993, 119:312–323.
- Janssen HLA, Gerken G, Carreno V, et al.: Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999, 30:238–243. CrossRef
- Perrillo RP: Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001, 120:1009–1022. This is a well-referenced review of the clinical significance of serum ALT flares during chronic HBV infection, including those that occur in association with interferon and nucleoside analogues. CrossRef
- Perrillo R, Tamburro C, Regenstein F, et al.: Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995, 109:908–916. CrossRef
- Nair S, Perrillo R: Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 2001, 34:1021–1026. The authors examine the relationship between ALT flares during interferon therapy and virologic response in 163 patients. The degree of flare was an excellent predictor of response in patients with a high level (>100 pg/mL) of HBV DNA at baseline. CrossRef
- Zeuzem S, Feinman SV, Rasenack J, et al.: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000, 343:1666–1672. CrossRef
- Torresi J, Locarnini S: Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 2000, 118:S83-S103. This is an authoritative summary of the mechanisms of action of interferon and nucleoside analogues. Each of the nucleoside analogues with activity against HBV is discussed, as is the problem of resistance to lamivudine. CrossRef
- Boni C, Penna A, Ocg GS, et al.: Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001, 33:963–971. CrossRef
- Honkoop P, De Man RA, Niesters HGM, et al.: Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000, 32:635–639. CrossRef
- Van Nunen AB, Hansen B, Suh D, et al.: Durability of HBeAg seroconversion in chronic hepatitis B patients after lamivudine, alpha interferon, or lamivudine-alpha interferon combination therapy [abstract]. J Hepatol 2001, 34(suppl1):155. CrossRef
- Song B-C, Suh DJ, Lee HC, et al.: Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000, 32:803–806. CrossRef
- Schiff ER, Heathcote J, Dienstag JL, et al.: Improvements in liver histology and cirrhosis with extended lamivudine therapy [abstract]. Hepatology 2000, 32:296A.
- Chien R-N, Liaw Y-F, Atkins M, and the Asian Hepatitis Lamivudine Trial Group: Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999, 30:770–774. This study evaluated 358 Asian patients and convincingly demonstrated that pretherapy ALT is the strongest determinant for HBeAg seroconversion during lamivudine therapy. The highest rate of seroconversion (64%) occurred in patients with ALT levels in excess of five times the upper limit of normal. CrossRef
- Hunt CM, McGill JM, Allen MI, Condreay LD: Clinical relevance of hepatitis B viral mutations. Hepatology 2000, 31:1037–1044. CrossRef
- Melegari M, Scaglioni PP, Wands JR: Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1997, 27:628–633. CrossRef
- Perrillo R, Rakela J, Dienstag J, et al.: Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999, 29:1581–1586. CrossRef
- Liaw Y-F, Chien R-N, Yeh C-T, et al.: Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999, 30:567–572. CrossRef
- Mutimer D, Pillay D, Shields P, et al.: Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000, 46:107–113. CrossRef
- Peters MG, Singer G, Howard T, et al.: Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient. Transplantation 2000, 68:1912–1914. CrossRef
- De Man RA, Marcellin P, Habal F, et al.: A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology 2000, 32:413–417. CrossRef
- Tillmann HL, Trautwein C, Bock T, et al.: Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 1999, 30:244–256. CrossRef
- Hadziyannis SJ, Manesis EK, Papakonstantinou A: Oral ganciclovir treatment in chronic hepatitis B virus infection: a pilot study. J Hepatology 1999, 31:210–214. CrossRef
- Marcellin P, Chang T-T, Lim SG, et al.: GS-98-437 A doubleblind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg (+) chronic hepatitis B infection: 48 week results [abstract]. Hepatology 2001, 34:340A. CrossRef
- Xiong X, Flores C, Yang H, et al.: Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998, 28:1669–1673. CrossRef
- Perrillo RP, Schiff E, Yoshida E, et al.: Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000, 32:129–134. CrossRef
- Perrillo R, Schiff E, Hann H-WL, et al.: The addition of adefovir dipivoxil to lamivudine in decompensated chronic hepatitis B patients with YMDD variant HBV and reduced response to lamivudine: preliminary 24 week results [abstract]. Hepatology 2001, 34:349A.
- Innaimo SF, Seifer M, Bisacchi GS, et al.: Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997, 41:1444–1448.
- De Man RA, Wolters LMM, Nevens F, et al.: Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001, 34:578–582. CrossRef
- Ono SK, Kato N, Shiratori Y, et al.: The polymerase L528 mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001, 107:449–455. Using a transfected human hepatoma cell line, the authors determined the replication fitness and susceptibility of wild-type HBV and five lamivudine-resistant mutants to 11 compounds. Only adefovir and entecavir were effective against all five mutants, although higher doses were needed against double mutants. CrossRef
- Tassopoulos N, Cianciara J, Rizzetto M, et al.: Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy [abstract]. Hepatology 2001, 34:340A. CrossRef
- Lai C-L, Lam PF, Myers MW, et al.: Safe and potent suppression of hepatitis B virus (HBV) with L-deoxythymidine LDT): results of a dose-escalation trial [abstract]. Hepatology 2001, 321A.
- Peek SF, Cote PJ, Jacob JR, et al.: Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-B, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (marmota monax). Hepatology 2001, 33:25401–50266. CrossRef
- Shaw T, Locarnini S: Combination chemotherapy for hepatitis B virus: the final solution? Hepatology 2000, 32:430–432. This concise review focuses on the rationale for combinations of nucleoside analogues to treat chronic HBV infection. The significance attached to viral load and viral dynamics is discussed. The authors point out that the second phase of viral clearance in which cccDNA is eliminated may require adjuvant therapy with immunomodulators. CrossRef
- Colledge D, Locarnini S, Shaw T: Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997, 26:216–225.
- Lau G K-K K, Tsiang M, Hou J, et al.: Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 2000, 32:394–399. CrossRef
- Tsiang M, Rooney JF, Toole JJ, Gibbs CS: Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999, 29:1863–1869. A mathematical model is used to calculate the length of time necessary to reduce the total viral load in plasma down to one copy. The model takes into account the baseline viral load, free virus halflife, infected cell half-life, and the effectiveness of a drug to limit viral production. The authors conclude that this process would require an average of 517 days in patients treated with 30 mg of adefovir daily. CrossRef
- Dandri M, Burda MR, Will H, Petersen J: Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 2000, 32:139–146. CrossRef
- Korba BE, Cote P, Hornbuckle W, et al.: Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferon against WHV replication in chronic carrier woodchucks. Antivir Ther 2000, 5:95–104.
- Schalm SW, Heathcote J, Cianciara J, et al.: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000, 46:562–568. CrossRef
- Marques AR, Lau DTY, McKenzie R, et al.: Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B. J Infect Dis 1998, 178:1483–1487. CrossRef
- Seehofer D, Rayes N, Neuhaus R, et al.: Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation. Transpl Int 2000, 13(suppl 1):S359-S362. CrossRef
- Mutimer D, Dowling D, Cane P, et al.: Additive antiviral effects of lamivudine and alpha interferon in chronic hepatitis B infection. Antiviral Ther 2000, 5:273–277.
- Johnson MA, Jenkins JM, Bye C: A study of the pharmacokinetic interaction between lamivudine and alpha interferon. Eur J Clin Pharmacol 2000, 56:289–292. CrossRef
- Cohard M, Poynard T, Mathurin P, Zarski JP: Prednisoneinterferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis. Hepatology 1994, 20:1390–1398. CrossRef
- Liaw Y-F, Tsai S-L, Chien R-N, et al.: Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000, 32:604–609. CrossRef
- How will we use the new antiviral agents for hepatitis B?
Current Gastroenterology Reports
Volume 4, Issue 1 , pp 63-71
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation, 1514 Jefferson Highway, 70124, New Orleans, LA, USA